Nefazodone

Serotonin Reuptake Inhibitor — NERVOUS SYSTEM

Key facts

Nefazodone is an ofp drug in the Serotonin Reuptake Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1994. DrugCentral lists 34 molecular targets, including Htr2a, HTR2A and ADRA1A. Recorded indications include Major depressive disorder.

• Approval status: ofp (first approved 1994 by the FDA).
• Drug class: Serotonin Reuptake Inhibitor.
• Molecular targets: Htr2a, HTR2A, ADRA1A and Htr1a (34 listed in DrugCentral).
• Indications: Major depressive disorder.
• ATC code: N06AX06 (Other antidepressants).
• Molecular formula: C25H32ClN5O2; molecular weight 470.01 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Major depressive disorder

Off-label uses (1)

• Bipolar affective disorder, current episode depression

Contraindications (15)

• Angina pectoris
• Cerebrovascular accident
• Cerebrovascular disease
• Dehydration
• Disease of liver
• Disorder of cardiovascular system
• Epilepsy
• Hypovolemia
• Liver function tests abnormal
• Low blood pressure
• Mania
• Myocardial infarction
• Substance abuse
• Suicidal thoughts
• Upper gastrointestinal hemorrhage

Mechanism & targets

• Established pharmacologic class: Serotonin Reuptake Inhibitor

Molecular targets (34)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 2A	Htr2a	unknown	Ki 8.15
5-hydroxytryptamine receptor 2A	HTR2A	antagonist	Ki 8.00
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 7.79
5-hydroxytryptamine receptor 1A	Htr1a	unknown	Ki 7.28
5-hydroxytryptamine receptor 7	HTR7	unknown	Ki 7.15
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 7.14
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 7.10
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 6.92
Sodium-dependent serotonin transporter	Slc6a4	unknown	Ki 6.86
D(2) dopamine receptor	DRD2	unknown	Ki 6.75
Sodium-dependent serotonin transporter	SLC6A4	inhibitor	Kd 6.70
Transmembrane protein 97	TMEM97	unknown	Ki 6.65
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.63
5-hydroxytryptamine receptor 1B	HTR1B	unknown	Ki 6.58
D(4) dopamine receptor	DRD4	unknown	Ki 6.49
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.45
Sodium-dependent dopamine transporter	SLC6A3	unknown	Kd 6.44
Sodium-dependent noradrenaline transporter	SLC6A2	inhibitor	Kd 6.44
Histamine H1 receptor	HRH1	unknown	Ki 6.43
D(3) dopamine receptor	DRD3	unknown	Ki 6.42

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1994-12-22	FDA	—	BRISTOL MYERS SQUIBB

ATC classification

ATC code	Therapeutic hierarchy
N06AX06	NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: CYP2D6 · No Clinical PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	47.1
Intentional overdose	43.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nefazodone is on its molecule page.

• Molecular formula: C₂₅H₃₂ClN₅O₂
• Molecular weight: 470.01 g/mol
• CAS number: 83366-66-9
• InChIKey: VRBKIVRKKCLPHA-UHFFFAOYSA-N
• PubChem CID: 4449

CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nefazodone used for?

DrugCentral lists the following indications for Nefazodone: Major depressive disorder.

How does Nefazodone work?

Its molecular targets in DrugCentral include Htr2a, HTR2A (antagonist), ADRA1A and Htr1a.

When was Nefazodone first approved?

Nefazodone was first approved by the FDA in 1994.

What drug class does Nefazodone belong to?

Nefazodone is in the Serotonin Reuptake Inhibitor class.

What is the chemical formula of Nefazodone?

Nefazodone has the molecular formula C25H32ClN5O2 and a molecular weight of 470.01 g/mol.

Sources

• DrugCentral drug card 1890 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200492 — compound record and bioactivity
• PubChem CID 4449 — chemical identifiers
• DrugBank DB01149 — drug record
• FDA UNII 59H4FCV1TF — substance identity
• DailyMed: FDA labels for Nefazodone — current prescribing information (label search)
• UniProt P28223 (HTR2A) — target protein
• UniProt P35348 (ADRA1A) — target protein
• UniProt P34969 (HTR7) — target protein
• UniProt P28335 (HTR2C) — target protein
• UniProt P08908 (HTR1A) — target protein
• UniProt P28221 (HTR1D) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.